0

Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?

Shivashankar Damodaran, Christos E Kyriakopoulos, David F Jarrard

Urol Clin North Am. 2017 Nov;44(4):611-621.

PMID: 29107277

Abstract:

Androgen deprivation therapy (ADT) has been conventional treatment of newly diagnosed metastatic prostate cancer for more than 70 years. However, all patients eventually become castration-resistant and a significant proportion of life span is spent in the castration-resistant state. Prospective randomized control trials have incorporated early chemotherapy along with ADT based on the hypothesis that a significant level of resistance to ADT already exists in newly diagnosed metastatic prostate cancer and ADT exhibits synergistic antitumor activity with taxanes. We discuss the changing landscape of management of patients with newly diagnosed metastatic prostate cancer based on recently published landmark randomized trials.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP144413581 ADT ADT 144413-58-1 Price
qrcode